Drugs for Lethal Midline Granuloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 35)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Bevacizumab |
Approved, Investigational |
Phase 2 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
2 |
|
Cetuximab |
Approved |
Phase 1, Phase 2 |
|
205923-56-4 |
|
Synonyms:
ABP-494
ANTI EGFR
C225
C-225
C225|Erbitux®|IMC-225|IMC-C225
CETUXIMAB
Cétuximab
CETUXIMAB (GENETICAL RECOMBINATION)
|
Cetuximabum
CMAB009
CMAB-009
ERBITUX
IMC-225
IMC-C225
MOAB C225
|
|
3 |
|
Erlotinib |
Approved, Investigational |
Phase 1, Phase 2 |
|
183319-69-9, 183321-74-6 |
176870 |
Synonyms:
[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
[6,7-Bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine
11C Erlotinib
11C-Erlotinib
CP-358
CP-358,774
CP-358774
CP-35877401
CP-358774-01
ERLOTINIB
Erlotinib HCL
Erlotinib hydrochloride
Erlotinibum
|
HCL, Erlotinib
Hydrochloride, erlotinib
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
NSC 718781
NSC 718781|OSI 744|OSI-774|R 1415|Tarceva®
OSI 744
OSI 774
OSI-774
R 1415
R-1415
RG-1415
RO-508231
Tarceva
|
|
4 |
|
Aspartic acid |
Approved, Nutraceutical |
Phase 1, Phase 2 |
|
56-84-8 |
5960 |
Synonyms:
(+)-Aspartate
(+)-Aspartic acid
(+-)-Aspartic acid
(2S)-2-AMINOBUTANEDIOIC ACID
(2S)-2-AMINOSUCCINIC ACID
(2S)-Aspartate
(2S)-Aspartic acid
(L)-Aspartate
(L)-Aspartic acid
(R)-2-Aminosuccinate
(R,S)-Aspartic acid
(S)-(+)-Aspartate
(S)-(+)-Aspartic acid
(S)-2-Aminobutanedioate
(S)-2-Aminobutanedioic acid
(S)-2-Aminosuccinate
(S)-2-Aminosuccinic acid
(S)-Aminobutanedioate
(S)-Amino-butanedioate
(S)-Aminobutanedioic acid
(S)-Amino-butanedioic acid
(S)-Aspartate
(S)-Aspartic acid
[<sup>3</sup>H]-L-aspartate|[<sup>3</sup>H]-L-aspartic acid
2-Amino-3-methylsuccinate
2-Amino-3-methylsuccinic acid
2-Aminosuccinate
2-Aminosuccinic acid
ácido aspártico
Acidum asparticum
alpha-Aminosuccinate
alpha-Aminosuccinic acid
Aminosuccinate
Ammonium aspartate
Asp
Asparagate
Asparagic acid
Asparaginate
Asparaginic acid
Asparatate
ASPARTate
Aspartate magnesium hydrochloride
Aspartate, ammonium
Aspartate, calcium
Aspartate, dipotassium
Aspartate, disodium
Aspartate, magnesium
Aspartate, monopotassium
Aspartate, monosodium
Aspartate, potassium
Aspartate, sodium
|
ASPARTIC ACID
Aspartic acid, ammonium salt
Aspartic acid, calcium salt
Aspartic acid, dipotassium salt
Aspartic acid, disodium salt
Aspartic acid, hydrobromide
Aspartic acid, hydrochloride
Aspartic acid, magnesium (1:1) salt, hydrochloride, trihydrate
Aspartic acid, magnesium (2:1) salt
Aspartic acid, magnesium-potassium (2:1:2) salt
Aspartic acid, monopotassium salt
Aspartic acid, monosodium salt
Aspartic acid, potassium salt
Aspartic acid, sodium salt
Calcium aspartate
D
Dipotassium aspartate
Disodium aspartate
FEMA NO. 3656
H-Asp-OH
Hydrobromide aspartic acid
Hydrochloride aspartic acid
Hydrochloride, aspartate magnesium
L Aspartate
L Aspartic acid
L-(+)-Aspartate
L-(+)-Aspartic acid
L-Aminosuccinate
L-Aminosuccinic acid
L-Asp
L-Asp|L-aspartate
L-Asparagate
L-Asparagic acid
L-Asparaginate
L-Asparaginic acid
L-Asparaginsaeure
L-Asparaginsäure
L-Aspartate
L-Aspartic acid
Magnesiocard
Magnesium aspartate
MG 5 Longoral
MG5Longoral
MG-5-Longoral
Monopotassium aspartate
Monosodium aspartate
NSC-3973
Poly-DL-succinimide
Polysuccinimide
Potassium aspartate
Sodium aspartate
|
|
5 |
|
Arginine |
Approved, Investigational, Nutraceutical |
Phase 1, Phase 2 |
|
74-79-3 |
6322 |
Synonyms:
(2S)-2-Amino-5-(carbamimidamido)pentanoate
(2S)-2-Amino-5-(carbamimidamido)pentanoic acid
(2S)-2-AMINO-5-(DIAMINOMETHYLIDENEAMINO)PENTANOIC ACID
(2S)-2-AMINO-5-[(DIAMINOMETHYLIDENE)AMINO]PENTANOIC ACID
(2S)-2-Amino-5-guanidinopentanoate
(2S)-2-Amino-5-guanidinopentanoic acid
(2S)-2-AMINO-5-GUANIDINO-PENTANOIC ACID
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoic acid
(S)-2-Amino-5-guanidinopentanoate
(S)-2-Amino-5-guanidinopentanoic acid
(S)-2-Amino-5-guanidinovalerate
(S)-2-Amino-5-guanidinovaleric acid
2-Amino-5-guanidinovalerate
2-Amino-5-guanidinovaleric acid
5-[(Aminoiminomethyl)amino]-L-norvaline
Arg
Arginina
Arginine
|
Arginine hydrochloride
Arginine, L isomer
Arginine, L-isomer
DL Arginine acetate, monohydrate
DL-Arginine acetate, monohydrate
Hydrochloride, arginine
L Arginine
L-(+)-Arginine
L-a-Amino-D-guanidinovalerate
L-a-Amino-D-guanidinovaleric acid
L-alpha-Amino-delta-guanidinovalerate
L-alpha-Amino-delta-guanidinovaleric acid
L-Arg
L-Arginin
L-ARGININE
L-Isomer arginine
Monohydrate DL-arginine acetate
N5-(Aminoiminomethyl)-L-ornithine
NSC-206269
R
|
|
6 |
|
Glycine |
Approved, Nutraceutical, Vet_approved |
Phase 1, Phase 2 |
|
56-40-6 |
750 |
Synonyms:
[<sup>14</sup>C]-glycine
2-Aminoacetate
2-Aminoacetic acid
Acid, aminoacetic
Aciport
Aminoacetate
Amino-acetate
Amino-acetic acid
AMINOACETIC ACID
AMINOESSIGSAEURE
AMINOESSIGSÄURE
Aminoethanoate
AMINOETHANOIC ACID
Calcium salt glycine
Cobalt salt glycine
Copper salt glycine
FEMA NO. 3287
G
Glicina
Glicoamin
GLY
GLYCIN
GLYCINE
Glycine carbonate (1:1), monosodium salt
Glycine carbonate (2:1), monolithium salt
Glycine carbonate (2:1), monopotassium salt
Glycine carbonate (2:1), monosodium salt
Glycine hydrochloride
Glycine hydrochloride (2:1)
Glycine phosphate
|
Glycine phosphate (1:1)
Glycine sulfate (3:1)
Glycine, calcium salt
Glycine, calcium salt (2:1)
Glycine, cobalt salt
Glycine, copper salt
Glycine, monoammonium salt
Glycine, monopotasssium salt
Glycine, monosodium salt
Glycine, sodium hydrogen carbonate
GLYCOCOLL
GLYCOLIXIR
Glycosthene
GLYKOKOLL
GLYZIN
Gyn-hydralin
H2N-CH2-COOH
HGLY
Hydrochloride, glycine
LEIMZUCKER
Monoammonium salt glycine
Monopotasssium salt glycine
Monosodium salt glycine
NSC-25936
Padil
Phosphate, glycine
Salt glycine, monoammonium
Salt glycine, monosodium
جلايسين
|
|
7 |
|
Immunoglobulins, Intravenous |
|
Phase 2 |
|
|
|
8 |
|
Immunoglobulins |
|
Phase 2 |
|
|
|
9 |
|
Angiogenesis Inhibitors |
|
Phase 2 |
|
|
|
10 |
|
Antibodies, Monoclonal |
|
Phase 2 |
|
|
|
11 |
|
Antibodies |
|
Phase 2 |
|
|
|
12 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
13 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
14 |
|
Protein Kinase Inhibitors |
|
Phase 1, Phase 2 |
|
|
|
15 |
|
Radiopharmaceuticals |
|
Phase 1, Phase 2 |
|
|
|
16 |
|
Neurotransmitter Agents |
|
Phase 1, Phase 2 |
|
|
|
17 |
|
Arginyl-glycyl-aspartic acid |
|
Phase 1, Phase 2 |
|
|
3328704 |
Synonyms:
2-({2-[(2-amino-5-carbamimidamido-1-hydroxypentylidene)amino]-1-hydroxyethylidene}amino)butanedioate
|
|
|
18 |
|
Fluorodeoxyglucose F18 |
|
Phase 1, Phase 2 |
|
|
|
19 |
|
Fluorides |
|
Phase 1, Phase 2 |
|
|
|
20 |
|
N-Methylaspartate |
|
Phase 1, Phase 2 |
|
|
|
21 |
|
Everolimus |
Approved |
Phase 1 |
|
159351-69-6 |
70789204 6442177 |
Synonyms:
001, RAD
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-HYDROXYETHYL)RAPAMYCIN
Afinitor
AFINITOR DISPERZ
Afinitor®|Certican®|RAD-001|RAD001|rapamycin, 42-O-(2-hydroxyethyl)-|Zortress®
Certican
EVEROLIMUS
évérolimus
RAD 001
|
RAD 666
RAD, SDZ
RAD001
RAD-001
RAD-666
SDZ RAD
SDZ-RAD
VOTUBIA
ZORTRESS
|
|
22 |
|
Sirolimus |
Approved, Investigational |
Phase 1 |
|
53123-88-9 |
5284616 6436030 |
Synonyms:
(-)-Rapamycin
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
Antibiotic ay 22989
AY-22989
AY-22989|Fyarro® (sirolimus albumin-bound particles)|Rapamune®|rapamycin|WY-090217
L04AA10
NSC-226080
Perceiva
RAPA
Rapammune
|
Rapamune
Rapamycin
Rapamysin
RPM
Sirolimus
Sirolimús
Sirolimusum
SM-88 COMPONENT SIROLIMUS
WY-090217
|
|
23 |
|
Lenograstim |
Approved, Investigational |
Phase 1 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
24 |
|
Fluorouracil |
Approved |
Phase 1 |
|
51-21-8 |
3385 |
Synonyms:
5 Fluorouracil
5 Fluorouracil biosyn
5 FU
5 FU lederle
5 FU medac
5 HU hexal
5.F.U.
5-Fluoracil
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluracil
5FU
5-FU
5-FU lederle
5-FU medac
5-HU hexal
ACCUSITE
ACTIKERALL
Adrucil
Allergan brand OF fluorouracil
Arumel
Biosyn brand OF fluorouracil
Carac
Carzonal
CSP Brand OF fluorouracil
Dakota brand OF fluorouracil
Dakota, fluorouracile
Dermatech brand OF fluorouracil
Dermik brand OF fluorouracil
Effluderm
Efudex
Efudix
Efurix
Ferrer brand OF fluorouracil
Fluoro Uracil
Fluoro uracile icn
Fluoroblastin
Fluoroplex
Fluorouracil
Fluorouracil gry
Fluorouracil mononitrate
Fluorouracil monopotassium salt
Fluorouracil monosodium salt
Fluorouracil potassium salt
FLUORO-URACIL ROCHE
Fluorouracil teva brand
|
Fluorouracile dakota
Fluoro-uracile icn
Fluorouracil-gry
Fluorouracilo
Fluorouracilo ferrer far
Fluorouracilum
Fluoruracil
Fluouracil
Fluracedyl
FLURACIL
Fluracilum
Fluri
Fluril
Fluro Uracil
Flurodex
Flurouracil
Ftoruracil
FU
Gry brand OF fluorouracil
Haemato brand OF fluorouracil
Haemato fu
Haemato-fu
Hexal brand OF fluorouracil
ICN brand OF fluorouracil
Kecimeton
Medac brand OF fluorouracil
Neocorp brand OF fluorouracil
Neofluor
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
RO-29757
RO-2-9757
Roche brand OF fluorouracil
Teva brand OF fluorouracil
Timazin
TOLAK
Ulup
URF
|
|
25 |
|
Hydroxyurea |
Approved |
Phase 1 |
|
127-07-1 |
3657 |
Synonyms:
Biosupressin
Carbamohydroxamate
Carbamohydroxamic acid
Carbamohydroximate
Carbamohydroximic acid
Carbamohydroxyamic acid
Carbamoyl oxime
Carbamyl hydroxamate
Carbamyl hydroxamic acid
Droxia
Droxia®|Hydrea®|hydroxycarbamide|Siklos®|SQ-1089|Xromi®
Hidrix
Hidroxicarbamida
HU
Hydrea
Hydreia
Hydroxicarbamidum
Hydroxycarbamid
Hydroxycarbamide
Hydroxycarbamidum
|
Hydroxycarbamine
Hydroxyharnstoff
Hydroxylurea
HYDROXYUREA
Hydura
Hydurea
Idrossicarbamide
Idrossicarbamide [Dcit]
Litaler
Litalir
N-Carbamoylhydroxylamine
N-HYDROXYUREA
NSC-32065
Oncocarbide
Onco-Carbide
Oxyurea
SIKLOS
SQ-1089
Sterile Urea
Ureaphil
|
|
26 |
|
Irinotecan |
Approved, Investigational |
Phase 1 |
|
97682-44-5, 100286-90-6 |
60838 |
Synonyms:
(+)-Irinotecan
7 Ethyl 10 hydroxycamptothecin
7-Ethyl-10-hydroxycamptothecin
Biotecan
Camptosar
Camptothecin 11
Camptothecin-11
CP0
CPT 11
CPT11
CPT-11
HSDB 7607
Irinophore C
IRINOTECAN
|
Irinotecan Hcl
Irinotecan hydrochloride
Irinotecan hydrochloride trihydrate
Irinotecan lactone
Irinotecan mylan
IRINOTECAN, CPT-11
Irinotecanum
Irinotecanum [INN-Latin]
Irrinotecan
NK012 Compound
sn 38
sn-38
sn38 CPD
|
|
27 |
|
7-Hydroxystaurosporine |
Experimental, Investigational |
Phase 1 |
|
112953-11-4 |
4616292 72271 |
Synonyms:
7-Hydroxystaurosporine
7-Hydroxy-staurosporine
KRX-0601|KRX0601|UCN 01|UCN-01
|
|
|
28 |
|
Cola |
|
Phase 1 |
|
|
|
29 |
|
Immunosuppressive Agents |
|
Phase 1 |
|
|
|
30 |
|
Antimetabolites |
|
Phase 1 |
|
|
|
31 |
|
Endothelial Growth Factors |
|
Phase 1 |
|
|
|
32 |
|
Mitogens |
|
Phase 1 |
|
|
|
33 |
|
Liver Extracts |
|
Phase 1 |
|
|
|
34 |
|
topoisomerase I inhibitors |
|
Phase 1 |
|
|
|
35 |
|
Gefitinib |
Approved, Investigational |
|
|
184475-35-2 |
123631 |
Synonyms:
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
GEFITINIB
Gefitinibum
Iressa
Iressa®|ZD 1839|ZD1839
Irressat
|
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
ZD 1839
ZD1839
ZD-1839
|
|
Interventional clinical trials:
(show all 11)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage |
Completed |
NCT00492089 |
Phase 2 |
bevacizumab;placebo |
2 |
A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma |
Completed |
NCT00101348 |
Phase 1, Phase 2 |
erlotinib hydrochloride |
3 |
Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis |
Completed |
NCT01806675 |
Phase 1, Phase 2 |
18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2 |
4 |
A Phase I Evaluation of Cetuximab and RAD001 in Patients With Solid Tumors |
Completed |
NCT01637194 |
Phase 1 |
everolimus |
5 |
A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer |
Completed |
NCT00470496 |
Phase 1 |
HPPH;photodynamic therapy |
6 |
A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vascular Endothelial Growth Factor) In Addition To Flourouracil And Hydroxyurea As Initial Chemotherapy With Concomitant Radiotherapy (B-FHX) For Poor Prognosis Head And Neck Cancer |
Completed |
NCT00023959 |
Phase 1 |
hydroxyurea;fluorouracil |
7 |
Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC #707545) in Patients With Solid Tumors. |
Completed |
NCT00089362 |
Phase 1 |
alvespimycin hydrochloride |
8 |
A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer |
Completed |
NCT00397384 |
Phase 1 |
cetuximab;erlotinib hydrochloride |
9 |
Phase I Study of OSI-774 (NSC 718781) for Solid Tumors in Patients With Hepatic or Renal Dysfunction |
Completed |
NCT00030498 |
Phase 1 |
erlotinib hydrochloride |
10 |
A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II) |
Completed |
NCT00031681 |
Phase 1 |
7-hydroxystaurosporine;irinotecan hydrochloride |
11 |
Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger) |
Completed |
NCT00068497 |
|
gefitinib |
|